Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $32,127.60 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Masaru Matsuda sold 1,230 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.12, for a total value of $32,127.60. Following the sale, the insider owned 126,171 shares of the company’s stock, valued at $3,295,586.52. The trade was a 0.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arcutis Biotherapeutics Trading Down 4.3%

NASDAQ ARQT opened at $25.29 on Friday. Arcutis Biotherapeutics, Inc. has a one year low of $13.69 and a one year high of $31.77. The company’s 50 day moving average price is $26.05 and its 200 day moving average price is $24.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.46 and a current ratio of 2.92. The firm has a market capitalization of $3.16 billion, a price-to-earnings ratio of 120.43 and a beta of 1.49.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.05. Arcutis Biotherapeutics had a net margin of 6.15% and a return on equity of 15.05%. The company had revenue of $129.86 million during the quarter, compared to the consensus estimate of $118.85 million. On average, sell-side analysts predict that Arcutis Biotherapeutics, Inc. will post 0.16 EPS for the current year.

Key Stories Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong second-quarter performance: Arcutis reported adjusted EPS of $0.11, exceeding estimates of $0.06–$0.09 and improving from a $0.13 loss a year earlier. Revenue rose 59% year over year to $129.9 million, beating the $118.9 million consensus estimate. Arcutis Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Raised sales outlook and expanding ZORYVE opportunity: Management increased 2026 net product-sales guidance to $525 million–$540 million. ZORYVE also gained an expanded pediatric plaque-psoriasis approval, while the FDA accepted an application for use in infants with atopic dermatitis. Arcutis Second-Quarter 2026 Financial Results
• Positive Sentiment: Analyst support remains favorable: Needham raised its price target from $36 to $40 and reiterated a Buy rating. HC Wainwright’s 2027 estimates project quarterly EPS rising from $0.08 in the first quarter to $0.48 in the fourth quarter, suggesting expectations for continued earnings growth. Benzinga analyst report
• Neutral Sentiment: Commercial leadership changes: Arcutis announced key changes to its commercial leadership team. The move could support execution, but investors may initially view management transitions as an operational uncertainty. Arcutis Announces Key Commercial Leadership Changes
• Neutral Sentiment: Insider selling was limited and prearranged: Three executives sold a combined 6,560 shares to cover tax withholding on vested equity awards under Rule 10b5-1 plans, reducing the bearish significance of the transactions.

Hedge Funds Weigh In On Arcutis Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS Group AG boosted its stake in shares of Arcutis Biotherapeutics by 10.0% during the 4th quarter. UBS Group AG now owns 3,243,432 shares of the company’s stock valued at $94,189,000 after buying an additional 294,994 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in Arcutis Biotherapeutics in the third quarter valued at $1,319,000. Kornitzer Capital Management Inc. KS boosted its stake in Arcutis Biotherapeutics by 55.1% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 175,870 shares of the company’s stock valued at $4,143,000 after acquiring an additional 62,485 shares during the last quarter. Vanguard Group Inc. grew its holdings in Arcutis Biotherapeutics by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 7,253,936 shares of the company’s stock worth $210,654,000 after acquiring an additional 107,846 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Arcutis Biotherapeutics in the 4th quarter valued at about $26,136,000.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ARQT. Morgan Stanley increased their price target on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday. Needham & Company LLC upped their target price on Arcutis Biotherapeutics from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. Weiss Ratings upgraded Arcutis Biotherapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday. Guggenheim raised their target price on Arcutis Biotherapeutics from $35.00 to $38.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wall Street Zen raised Arcutis Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Arcutis Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $35.57.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.